JP2019529571A - 機能性ｒｎａと小分子薬の治療用複合体、およびナノ粒子送達ビヒクル - Google Patents

機能性ｒｎａと小分子薬の治療用複合体、およびナノ粒子送達ビヒクル Download PDF

Info

Publication number
JP2019529571A
JP2019529571A JP2019538580A JP2019538580A JP2019529571A JP 2019529571 A JP2019529571 A JP 2019529571A JP 2019538580 A JP2019538580 A JP 2019538580A JP 2019538580 A JP2019538580 A JP 2019538580A JP 2019529571 A JP2019529571 A JP 2019529571A
Authority
JP
Japan
Prior art keywords
composition
functional rna
rna molecule
small molecule
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019538580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529571A5 (enExample
Inventor
ケー． ハファー，オマー
ケー． ハファー，オマー
Original Assignee
イーオーエス バイオサイエンシーズ，インコーポレイテッド
イーオーエス バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーオーエス バイオサイエンシーズ，インコーポレイテッド, イーオーエス バイオサイエンシーズ，インコーポレイテッド filed Critical イーオーエス バイオサイエンシーズ，インコーポレイテッド
Publication of JP2019529571A publication Critical patent/JP2019529571A/ja
Publication of JP2019529571A5 publication Critical patent/JP2019529571A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019538580A 2016-10-03 2017-10-03 機能性ｒｎａと小分子薬の治療用複合体、およびナノ粒子送達ビヒクル Pending JP2019529571A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403595P 2016-10-03 2016-10-03
US62/403,595 2016-10-03
PCT/US2017/054884 WO2018067526A1 (en) 2016-10-03 2017-10-03 Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles

Publications (2)

Publication Number Publication Date
JP2019529571A true JP2019529571A (ja) 2019-10-17
JP2019529571A5 JP2019529571A5 (enExample) 2020-11-12

Family

ID=61831202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538580A Pending JP2019529571A (ja) 2016-10-03 2017-10-03 機能性ｒｎａと小分子薬の治療用複合体、およびナノ粒子送達ビヒクル

Country Status (7)

Country Link
US (1) US20190240344A1 (enExample)
EP (1) EP3518939A4 (enExample)
JP (1) JP2019529571A (enExample)
CN (1) CN109890393A (enExample)
AU (1) AU2017339456A1 (enExample)
CA (1) CA3039040A1 (enExample)
WO (1) WO2018067526A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
RU2682335C2 (ru) 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
WO2019136005A1 (en) * 2018-01-02 2019-07-11 Cedars-Sinai Medical Center Nanoparticles for the targeted delivery of therapeutic polypeptides
CN109432430B (zh) * 2018-11-22 2021-12-17 华南理工大学 一种siRNA和抗癌药物疏水性复合物及其制备方法与应用
CN119015258A (zh) * 2019-09-06 2024-11-26 加利福尼亚大学董事会 核酸介导的治疗剂的递送

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506417A (ja) * 1999-08-09 2003-02-18 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
US20100331273A1 (en) * 2007-07-06 2010-12-30 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513843T1 (de) * 2002-09-25 2011-07-15 Univ Massachusetts Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
JP5252618B2 (ja) * 2007-10-26 2013-07-31 独立行政法人産業技術総合研究所 ＲＮＡ干渉効果が高い芳香環修飾ｓｉＲＮＡ
WO2010085665A2 (en) * 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
RU2682335C2 (ru) * 2014-01-17 2019-03-19 Сидарс-Синай Медикал Сентр Рецептор-направленные конструкции и их применение
MX2018014576A (es) * 2016-05-27 2019-06-06 Cedars Sinai Medical Center Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506417A (ja) * 1999-08-09 2003-02-18 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
US20100331273A1 (en) * 2007-07-06 2010-12-30 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANGEW. CHEM. INT. ED., vol. 45, JPN6021042305, 2006, pages 8149 - 8152, ISSN: 0004779035 *
BIOMATERIALS, vol. 32, JPN6021042306, 2011, pages 2124 - 2132, ISSN: 0004624367 *

Also Published As

Publication number Publication date
US20190240344A1 (en) 2019-08-08
EP3518939A1 (en) 2019-08-07
EP3518939A4 (en) 2020-06-24
CN109890393A (zh) 2019-06-14
CA3039040A1 (en) 2018-04-12
AU2017339456A1 (en) 2019-04-11
WO2018067526A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
US20250255978A1 (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
JP2019529571A (ja) 機能性ｒｎａと小分子薬の治療用複合体、およびナノ粒子送達ビヒクル
JP2023065583A (ja) 癌治療用の新規な組換え原形質膜をベースとする小胞体
Joshi et al. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression
JP2024503623A (ja) カプセル化ｒｎａポリヌクレオチド及び使用方法
JP2024122983A (ja) 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス
US20240360445A1 (en) CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
CN103655475B (zh) 靶向的脂质体
WO2017138925A1 (en) Antitumour combinations of antisense oligonucleotides and anticancer agents
US20170143630A1 (en) Compositions and methods for treating ewing sarcoma
EP3577217B1 (en) Retargeting of viruses or vlps
Ferreira et al. Smart Targeted-Nanocarriers for Cancer Therapeutics
US20210077575A1 (en) Nanoparticles for the targeted delivery of therapeutic polypeptides
Seraj et al. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects
US20240238418A1 (en) Car t cell therapy method
US12139713B2 (en) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
WO2024130257A2 (en) In vivo and ex vivo production of car-neutrophils and use thereof to treat and image cancer
TW202402305A (zh) 癌症治療之免疫增強
WO2024204685A1 (ja) 癌の治療および／または予防のための医薬組成物
HK1173184A (en) Sparc antisense compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220524